FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W103408> ?p ?o ?g. }

• W103408 endingPage "303" @default.
• W103408 startingPage "295" @default.
• W103408 abstract "OBJECTIVES Adult GH deficiency (GHD) is associated with profound alterations in body composition, lipid profiles and quality of life which frequently improve after GH therapy. However, the beneficial effects of treatment are not derived by all and consequently some scepticism persists with regard to the use of GH therapy in adults. We assessed whether a 3-month therapeutic assessment with GH therapy could be used to determine which GHD adults should be treated over the longer term. We also assessed the continued prescription of GH by general practitioners (GPs) following the initial therapeutic assessment. DESIGN A three month open therapeutic trial of GH in GHD adults. Patients were treated with GH at an initial dose of 0.01 iU/kg/d, increased after 1 month to 0.015 iU/kg/d for males and 0.02 iU/kg/d for females. After completion of the three months the continued prescription of GH by the GPs was assessed. PATIENTS All adult GHD patients were considered for GH therapy. Thirty-nine GHD adults wanted GH therapy (group 1) and their baseline characteristics such as age, duration of GHD, and IGF-1 concentration were compared with 24 subjects who declined to receive GH (group 2). MEASUREMENTS Measurements of body composition using bioelectrical impedance analysis, lipids and quality of life measured using a dedicated questionnaire were made before and after GH therapy. The response of the general practitioners to continued GH therapy after the initial therapeutic assessment was also noted. RESULTS Compared with subjects who declined GH therapy (group 2), subjects of group 1 were younger (46.4 ± 14.4 vs. 54.2 ± 15.7 years, P < 0.05) and had lower peak GH responses to provocative testing (1.4 ± 2.1 vs. 2.9 ± 2.7 mU/l, P < 0.001), though there were no differences between IGF-1 concentration (11.7 ± 6.2 vs. 14.2 ± 7.9 nmol/l). Following three months of GH therapy, there were significant improvements in all measured parameters including increased free fat mass (50.2 vs. 52.4 kg, P < 0.005) and total body water (37 vs. 38.7 l, P < 0.005), reduced fat mass (31.6 vs. 29.8 kg, P < 0.005), reduced AGHDA score (7 vs. 4, P < 0.001) and reduced cholesterol (6.3 vs. 5.8 mmol/l, P < 0.001), LDL (4 vs. 3.33 mmol/l, P < 0.001) and cholesterol/HDL ratio (5.57 vs. 4.67, P < 0.001). IGF-1 concentrations were significantly increased following treatment (12 vs. 32.4 nmol/l). Six subjects decided to discontinue GH therapy, 2 before the end of the study due to potential drug-related side-effects and 4 subjects derived no benefit from treatment. Despite the demonstrable benefits of treatment for the remaining 33 GHD adults, 6 GPs refused to continue to prescribe GH therapy for reasons of lack of familiarity with the drug or advice from their health authority. CONCLUSION Patients who wanted GH therapy were usually younger and more severely GHD than counterparts who elect not to be treated. However, a therapeutic trial of GH therapy is required to distinguish those subjects who derive benefit from treatment. We have shown that three months of low dose GH therapy is a sufficient period to elicit significant beneficial responses in quality of life, body composition parameters and lipids for the majority of patients and appears to be a sufficient period for patients to decide whether they want longer term therapy. The initial therapeutic trial also provides the objective evidence for the general practitioners to decide upon the continued prescription of therapy. Despite the positive evidence provided by this study, a small minority of general practitioners still refuse to prescribe GH therapy." @default.
• W103408 created "2016-06-24" @default.
• W103408 creator A5008355893 @default.
• W103408 creator A5010946693 @default.
• W103408 creator A5033963717 @default.
• W103408 creator A5061014524 @default.
• W103408 creator A5084599833 @default.
• W103408 creator A5086235763 @default.
• W103408 creator A5088158896 @default.
• W103408 creator A5091816040 @default.
• W103408 date "2000-03-01" @default.
• W103408 modified "2023-09-27" @default.
• W103408 title "A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners" @default.
• W103408 cites W1908144174 @default.
• W103408 cites W194386581 @default.
• W103408 cites W1946263363 @default.
• W103408 cites W1987469137 @default.
• W103408 cites W1988064413 @default.
• W103408 cites W2020108509 @default.
• W103408 cites W2021368986 @default.
• W103408 cites W2022317574 @default.
• W103408 cites W2023206717 @default.
• W103408 cites W2050255044 @default.
• W103408 cites W2052171570 @default.
• W103408 cites W2056415845 @default.
• W103408 cites W2063693194 @default.
• W103408 cites W2074022842 @default.
• W103408 cites W2074323061 @default.
• W103408 cites W2082524369 @default.
• W103408 cites W2095611917 @default.
• W103408 cites W2098999072 @default.
• W103408 cites W2116404316 @default.
• W103408 cites W2120108803 @default.
• W103408 cites W2132374244 @default.
• W103408 cites W2137502920 @default.
• W103408 cites W2153868160 @default.
• W103408 cites W2181043099 @default.
• W103408 cites W2316750241 @default.
• W103408 cites W2331609610 @default.
• W103408 cites W4251818304 @default.
• W103408 doi "https://doi.org/10.1046/j.1365-2265.2000.00964.x" @default.
• W103408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10718827" @default.
• W103408 hasPublicationYear "2000" @default.
• W103408 type Work @default.
• W103408 sameAs 103408 @default.
• W103408 citedByCount "11" @default.
• W103408 countsByYear W1034082016 @default.
• W103408 countsByYear W1034082021 @default.
• W103408 crossrefType "journal-article" @default.
• W103408 hasAuthorship W103408A5008355893 @default.
• W103408 hasAuthorship W103408A5010946693 @default.
• W103408 hasAuthorship W103408A5033963717 @default.
• W103408 hasAuthorship W103408A5061014524 @default.
• W103408 hasAuthorship W103408A5084599833 @default.
• W103408 hasAuthorship W103408A5086235763 @default.
• W103408 hasAuthorship W103408A5088158896 @default.
• W103408 hasAuthorship W103408A5091816040 @default.
• W103408 hasConcept C102652120 @default.
• W103408 hasConcept C121608353 @default.
• W103408 hasConcept C126322002 @default.
• W103408 hasConcept C134018914 @default.
• W103408 hasConcept C159110408 @default.
• W103408 hasConcept C187212893 @default.
• W103408 hasConcept C2426938 @default.
• W103408 hasConcept C2778491484 @default.
• W103408 hasConcept C2779951463 @default.
• W103408 hasConcept C2779952775 @default.
• W103408 hasConcept C2780221984 @default.
• W103408 hasConcept C2780275930 @default.
• W103408 hasConcept C2984496839 @default.
• W103408 hasConcept C33872192 @default.
• W103408 hasConcept C530470458 @default.
• W103408 hasConcept C71315377 @default.
• W103408 hasConcept C71924100 @default.
• W103408 hasConcept C98274493 @default.
• W103408 hasConceptScore W103408C102652120 @default.
• W103408 hasConceptScore W103408C121608353 @default.
• W103408 hasConceptScore W103408C126322002 @default.
• W103408 hasConceptScore W103408C134018914 @default.
• W103408 hasConceptScore W103408C159110408 @default.
• W103408 hasConceptScore W103408C187212893 @default.
• W103408 hasConceptScore W103408C2426938 @default.
• W103408 hasConceptScore W103408C2778491484 @default.
• W103408 hasConceptScore W103408C2779951463 @default.
• W103408 hasConceptScore W103408C2779952775 @default.
• W103408 hasConceptScore W103408C2780221984 @default.
• W103408 hasConceptScore W103408C2780275930 @default.
• W103408 hasConceptScore W103408C2984496839 @default.
• W103408 hasConceptScore W103408C33872192 @default.
• W103408 hasConceptScore W103408C530470458 @default.
• W103408 hasConceptScore W103408C71315377 @default.
• W103408 hasConceptScore W103408C71924100 @default.
• W103408 hasConceptScore W103408C98274493 @default.
• W103408 hasIssue "3" @default.
• W103408 hasLocation W1034081 @default.
• W103408 hasLocation W1034082 @default.
• W103408 hasOpenAccess W103408 @default.
• W103408 hasPrimaryLocation W1034081 @default.

• next